




Aprocitentan

Revised: April 15, 2024.

CASRN: 1103522-45-7



Drug Levels and Effects

Summary of Use during Lactation

No information is available on the clinical use of aprocitentan during breastfeeding. Because aprocitentan is more than 99% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is 41 hours and it might accumulate in the infant. Because no information is available on the use of aprocitentan during breastfeeding, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Aprocitentan

CAS Registry Number

1103522-45-7

Drug Class

Breast Feeding

Lactation

Milk, Human

Antihypertensive Agents

Endothelin Receptor Antagonists